Member Info for robbieishere

https://axisbiotix.com/

The potential is amazing. If the trial is successful then this could easily 20 bag from here. Time will tell.
Hopefully this webinar is about another one of our pillars. I strongly suspect it is!
https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwcc.on24.com%2F&eventid=2862442&sessionid=1&key=EF8159624874287E5856769EF73C207C®Tag=1930551&V2=false&sourcepage=register?partnerref=eventspagewebsiteprobiotic

Looks like the market is waking up to the potential here. Although the SP has roofed it over the last few days, if the trial is as good as we think it will be then 30p will look like an absolute bargain. GLA.

I assume will shall be getting a trading update this week on the H2 figures. Looking forward to our rerate to £1!

For me at present I think good value for our Market Cap is around £500m (approx £2.20) The BFS once released will easily justify this. I expect this to increase as progress on the Mine accelerates and personally at the end of 2021 I would not be surprised if the Market Cap is £750+. We can guess all we want to be long term it is very easy to see that this will be a £2bn+ company once 1st years production is out of the way.

£11m is assuming a 50/50 split with Winclove, I assume their percentage will reduce if demand rises as the product roles out.

I agree with Phoenix’s , if the psoriasis trial delivers then the sky is the limit. If just 1% of the psoriasis group in the states start using the product then it will pull in around £11m per annum. It is the type of product that if it delivers the results we all hope then he uptake will be vastly more than 1%. Drop the rest of the world market in on top then it might be challenging to keep up with demand!

Then we throw the Croda deal in and boom!

Been tipped again for 2021.

https://www.proactiveinvestors.co.uk/companies/news/937372/investment-tips-for-2021-some-ideas-from-the-professionals-937372.html

Ted, if everything is in place this will be valued more like 20x than 2x. If the psoriasis trial is successful then this alone would net significantly more reoccurring cash flow than the current market cap! Just in the US there is 6 Million registered members of the psoriasis society club, I’ll let you do the sums but 50p per person per day for a magic tablet that solves the skin issue is a small amount to pay!
That without the cosmetic deal that will get moving towards the end of 2021.

Everyone will have a view on the best point to exit any share, it will be a contributing of personal circumstances, news flow and share performance. Looking forward my view is I will have to top slice this once £2 is achieved as the holding in my portfolio would be to just too big ( I hope this is the case!) I will remain a long term holder indefinitely until news flow dictates otherwise but see some great times (& dividends) ahead.
My Bongo Drummer tells me that "exciting news" will be released soon. He's been on point for the last 6months so fingers crossed he's hitting the rhythm again.

GLA.

Can’t see it going as low as 72 again Tony, a small retrace is good and then it will move forward again. £1.50 before BFS, with £2 following shortly after.

Lol, my prediction of around £1.50 before BFS is looking a lot more likely now. GLA.

Personally I think it will be closer to £2. I think we will be close to £1.50 before the BFS is released. I expect a lot of institutions will start to buy in once the BFS is released.

Yep, I got in at 22 again at 50 and 80p. Absolutely convinced this will roof it. Friend of mine works for one of the top EV axial Motor companies (shame they are not listed!) who’s order book is just going ballistic and to give you a sense of scale their just their RD budget is TWICE our market capitalisation. Money being thrown into this industry is just mind blowing.
This is a win win.

Houston, we have lift off

Top up for me too. Can’t see the funding not going through. Looking forward to paying my mortgage off when the funding lands. Hopefully before the new year!

All aboard , next stop £1

Great RNS. this is my number 1 play for 2021. Roll on Jan for the BFS!
This has to be £1bn market cap within 2 years, although it might be £2bn lol.

Agree, I’ve been keeping an eye on this for a couple of months. Can see this sliding back to sub 15p before the big kicker in the spring. Sell for me at the moment, but will start to buy back once below 15p

Deal done. Result.

JOINT VENTURE CONDITIONAL AGREEMENTS COMPLETED

Ariana Resources plc ("Ariana" or the "Company"), the AIM-listed exploration and development company operating in Europe, is pleased to announce the completion of conditional agreements on its joint venture with Özaltin Holding A.S. ("Joint Venture" or "JV"), via its subsidiary, Özaltin Insaat, Ticaret and Sanayi A.S. (collectively "Özaltin") and with Proccea Construction Co. ("Proccea") (collectively "the Parties"). Özaltin will be acquiring 53% of both Pontid Madencilik Sanayi ve Ticaret A.S. ("Pontid"), the owner of the Salinbas Project ("Salinbas") and the existing Zenit Madencilik San. ve Tic. A.S. ("Zenit") joint venture which is currently owned by Ariana in a 50:50 partnership with Proccea.

The Joint Venture with Özaltin and Proccea involves the partial disposal of the interests of the Company in Zenit and Pontid in exchange for US$35.75 million in cash ("the Transaction"). On completion, Ariana will retain a 23.5% interest in the Joint Venture, as will Proccea. The Parties have also agreed to the sale of Ariana's remaining projects, under its subsidiary Galata, to Zenit for an additional US$2 million in cash (as announced on 2 December 2020).

Highlights:

· JV to continue the development of the 0.6Moz Red Rabbit Project and to advance the 1.5Moz Salinbas Project.

· JV to be owned 53% Özaltin, 23.5% Ariana, 23.5% Proccea, with Proccea as Manager.

· Cash payment to Ariana of US$37.75 million, before costs and taxation, inclusive of the sale of Ariana's remaining projects to Zenit.

· US$8 million to be committed by Özaltin to fund a Feasibility Study, EIA and additional permitting on Salinbas.

· Ariana to continue exploration across the JV projects with the aim of defining additional resources and in the pursuit of new project opportunities elsewhere.

· The Transaction remains conditional inter alia on Ariana shareholder approval, following the publication of a Circular to Shareholders and the satisfactory completion of a General Meeting of the Company. The Transaction is also conditional on the necessary regulatory approvals in Turkey.